Receptor-Mediated Drug Delivery Systems Targeting to Glioma
AbstractGlioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications. View Full-Text
Share & Cite This Article
Wang, S.; Meng, Y.; Li, C.; Qian, M.; Huang, R. Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials 2016, 6, 3.
Wang S, Meng Y, Li C, Qian M, Huang R. Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials. 2016; 6(1):3.Chicago/Turabian Style
Wang, Shanshan; Meng, Ying; Li, Chengyi; Qian, Min; Huang, Rongqin. 2016. "Receptor-Mediated Drug Delivery Systems Targeting to Glioma." Nanomaterials 6, no. 1: 3.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.